Investment Analysts’ Recent Ratings Updates for Xenon Pharmaceuticals (XENE)

by · The Markets Daily

A number of research firms have changed their ratings and price targets for Xenon Pharmaceuticals (NASDAQ: XENE):

  • 9/19/2026 – Xenon Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
  • 9/18/2026 – Xenon Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
  • 9/18/2026 – Xenon Pharmaceuticals had its price target lowered by Wells Fargo & Company from $69.00 to $64.00. They now have an “overweight” rating on the stock.
  • 9/18/2026 – Xenon Pharmaceuticals had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $46.00 price target on the stock, down from $90.00.
  • 9/18/2026 – Xenon Pharmaceuticals was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”. They now have a $46.00 price target on the stock, down from $90.00.
  • 9/18/2026 – Xenon Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $81.00 to $70.00. They now have an “outperform” rating on the stock.
  • 9/18/2026 – Xenon Pharmaceuticals had its price target lowered by Wedbush from $71.00 to $55.00. They now have an “outperform” rating on the stock.
  • 9/18/2026 – Xenon Pharmaceuticals had its price target lowered by Robert W. Baird from $97.00 to $90.00. They now have an “outperform” rating on the stock.
  • 9/18/2026 – Xenon Pharmaceuticals had its price target lowered by Needham & Company LLC from $78.00 to $60.00. They now have a “buy” rating on the stock.
  • 8/10/2026 – Xenon Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $74.00 price target on the stock.
  • 8/7/2026 – Xenon Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $82.00 to $81.00. They now have an “outperform” rating on the stock.
  • 8/1/2026 – Xenon Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.

Insider Activity at Xenon Pharmaceuticals

In other news, insider Christopher Kenney sold 7,068 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $60.25, for a total value of $425,847.00. Following the sale, the insider directly owned 2 shares in the company, valued at $120.50. The trade was a 99.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Steven Gannon sold 10,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total value of $640,600.00. Following the transaction, the director owned 1,870 shares of the company’s stock, valued at approximately $119,792.20. The trade was a 84.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.91% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its expertise in ion channels, which regulate the electrical activity of nerve cells, to discover and advance potential treatments for conditions with significant unmet medical needs.

Xenon’s leading investigational product is azetukalner (XEN1101), an oral, small-molecule potassium-channel opener being studied in epilepsy, including focal-onset seizures, and major depressive disorder.

Featured Stories